Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury

Peptides

Volumn 29, Issue 5, 2008, Pages 770-777

  Prosser, H C G ^a,b   Forster, M E ^a   Richards, A M ^b   Pemberton, C J ^b  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Ischemia reperfusion injury; Isolated heart; Palosuran; Urotensin II; URP

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CREATINE KINASE; PALOSURAN; RECOMBINANT UROTENSIN II; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RELATED PEPTIDE;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; VASODILATATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CORONARY VESSELS; CREATINE KINASE, MB FORM; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; PEPTIDE HORMONES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; REPERFUSION INJURY; UREA; UROTENSINS; VASODILATION;

RATTUS;

EID: 42049101979     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.013     Document Type: Article

References (44)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Behm D.J., Herold C.L., Camarda V., Aiyar N.V., and Douglas S.A. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur J Pharmacol 492 (2004) 113-116
3. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
4. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
5. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
6. Bousette N., Pottinger J., Ramli W., Ohlstein E.H., Dhanak D., Douglas S.A., et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
7. Case D.B., Wallace J.M., Keim H.J., Sealey J.E., and Laragh J.H. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive petients. Am J Med 60 (1976) 825-836
8. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Ségalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
9. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S.S., Fischli W., et al. Pharmacology of the urotensin-II receprtor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 (2004) 204-212
10. Conner A.C., Simms J., Hay D.L., Mahmoud K., Howitt S.G., Wheatley M., et al. Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin. Biochem Soc Trans 32 (2004) 843-846
11. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
12. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
13. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
14. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 (2002) 33-38
15. Gendron G., Gobeil F.J., Bélanger S., Gagnon S., Regoli D., and D'Orléans-Juste P. Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 26 (2005) 1468-1474
16. Gong H., Wang Y.-X., Zhu Y.-Z., Wang W.-W., Wang M.-J., Yao T., et al. Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol 97 (2004) 2228-2235
17. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2005) 1527-1531
18. Hassan G.S., Chouiali F., Saito T., Hu F., Douglas S.A., Ao Z., et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81 (2003) 125-128
19. Hassan G.S., Douglas S.A., Ohlstein E.H., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 (2005) 2564-2572
20. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 762-772
21. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
22. Hood S.G., Watson A.M.D., and May C.N. Cardiac actions of central but not peripheral urotensin II are prevented by β-adrenoceptor blockade. Peptides 26 (2005) 1248-1256
23. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402 (2000) 209-211
24. Khan S.Q., Bhandari S.S., Quinn P., Davies J.E., and Ng L.L. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 117 (2006) 323-328
25. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
26. Li L., Yuan W.-J., and Su D.-F. Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart. Acta Pharmacol Sin 25 (2004) 1444-1449
27. Opgaard O.S., Nothacker H.-P., Ehlert F.J., and Krause D.N. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406 (2000) 265-271
28. Pemberton C.J., Johnson M.L., Yandle T.G., and Espiner E.A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36 (2000) 355-359
29. Pemberton C.J., Raudsepp S.D., Yandle T.G., Cameron V.A., and Richards A.M. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 68 (2005) 109-117
30. Prosser H.C.G., Leprince J., Vaudry H., Richards A.M., Forster M.E., and Pemberton C.J. Cardiovascular effects of native and non-native UII and URP on rat and salmon hearts. Peptides 27 (2006) 3261-3268
31. Richards A.M., and Charles C. Urotensin II in the cardiovascular system. Peptides 25 (2004) 1795-1802
32. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
33. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
34. Russell F.D., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 (2004) 673-681
35. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
36. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
37. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
38. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
39. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
40. Watson A.M.D., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
41. Zhou P., Wu S., Yu C., Wang H., Tang C., Lin L., et al. Effects of urotensin II on isolated rat hearts under normal perfusion and ischaemia reperfusion. Sheng Li Xue Bao 55 (2003) 442-448
42. Zhu Y.Z., Wang Z.J., Zhu Y.C., Zhang L., Oakley R.M.E., Chung C.W., et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286 (2003) H830-H836
43. Zoccali C., Mallamaci F., Tripepi G., Cutrupi S., Pizzini P., and Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 69 (2006) 1253-1258
44. Zou Y., Nagai R., and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508 (2001) 57-60